Longevity & AgingAlzeCure's ACD856 Passes Safety Trial Paving Way for Alzheimer's and Depression Studies
AlzeCure's experimental drug ACD856 successfully completed a Phase Ib clinical trial, showing it was safe and well-tolerated at higher doses than previously tested. The drug reached measurable levels in both blood and cerebrospinal fluid, confirming it can access the brain. ACD856 works by enhancing the brain's own repair signals — specifically BDNF and NGF pathways — which support neuron survival, synaptic health, and reduce inflammation. These are mechanisms directly relevant to slowing Alzheimer's progression and treating depression. With this safety data in hand, the company plans to launch Phase II efficacy trials later in 2026, backed by a European Innovation Council grant. This milestone moves ACD856 from early safety testing into the critical phase where real therapeutic benefits will be measured.
